Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD EPS (Basic)

EPS (Basic) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$6.99-7.8%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.15-5.5%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$0.40-5.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$0.79-141%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$1.69-109%
Immunome logo
ImmunomeIMNM
-$0.48+7.7%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's EPS (basic)?
Kodiak Sciences Inc (KOD) reported EPS (basic) of -$0.94 in Q1 2026.
How has Kodiak Sciences Inc's EPS (basic) changed year-over-year?
Kodiak Sciences Inc's EPS (basic) increased by 13.8% year-over-year, from -$1.09 to -$0.94.
What is the long-term trend for Kodiak Sciences Inc's EPS (basic)?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's EPS (basic) has grown at a -4.3% compound annual growth rate (CAGR), from -$5.16 to -$4.32.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.